

References:

- **American Cancer Society** (2015). What is a risk factors for esophageal cancer. American cancer society 2015. Last Revised 3/2/2015.
- **American Cancer Society**. (2012). Cancer Fact and Figures 2012. Atlanta Ga: American Cancer Society.
- **Anthony DiMarino, Jr**, Stanley B. Benjamin, Firas H. Al-Kawas (2002). *Gastrointestinal disease: an endoscopic approach* (2nd ed.). Thorofare, NJ: Slack. p. 166.
- **Baeh PH**, Mcdonald G.B (1994). Esophageal infection: Risk factor, presentation, diagnosis and treatment. *Gastroenterology*; 106: 509 – 32.
- **Bagaria B**, Sood S, Sharma R, Lalwani S (2013). Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis). *Cancer Biol Med*; 10:148-57.
- **Borisch B**, Finke J, Henning I, Delacretaz F, Schneider J, Heitz P. U, et al (1992). Distribution and localization of Epstein-Barr virus subtypes A and B in AIDS-related lymphomas and lymphatic tissue HIV-positive patients. *J. Pathol.*, 168: 229-236.
- **Boyle P**, Levin B (2008). World Cancer Report. International Agency For Research On Cancer (IARC) lyon ; 342.
- **Buisson M**, Morand P, Genoulaz O, Bourgeat M. J, Micoud M, Seigneurin J. M (1994). Changes in the dominant Epstein-Barr virus type during human immunodeficiency virus infection. *J. Gen. Virol.*, 75 (Pt. 2): 431-437.
- **Burkitt D P A** (1958). Sarcoma involving the jaws in African children. *Br. J. Surg.* 46: 218-223.
- **Cancer Research UK**. (2014) .www.cancerresearchuk.org/about-cancer/Type/esophageal-cancer/. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666) and the Isle of Man (1103).
- **Cesarman E**, Mesri E. A (1999). Virus associated lymphomas. *Curr. Opin. Oncol.*, 11: 322-332.

- **Chang F**, Syrjanens, Wangl, Syrjanen K (1992). Infection agents in the etiology of esophageal cancer. *Gastroenterology*; 103:1336-48.
- **Cheng K K** (1994). The etiology of esophageal cancer in Chinese. *Semin oncol*; 21: 411 – 15.
- **Cheung A**, Kieff E (1982) long internal direct repeat in Epstein-Barr virus DNAs. *J Virol*. 44: 286-294.
- **Cheung. A**, Kieff, E (1982). Long internal direct repeat in Epstein – Barr virus DNAs. *The Journal Of virology*; 44: 286 – 294.
- **Clarke, P**, Schwemmie, M, Schiekinger, J (1991). Binding of EBV small RNA EBER -1 to double stranded RNA – activated protein kinase DAI, *Nucleic Acid Research* ; 19 : 243 – 8.
- **Clemens MJ** (1993). The small RNAs of Epstein Barr virus *MOL Biol Rep*; 17:81 – 92.
- **Colledge**, Nicki R, Walker, Brian R, Ralston, Stuart H (2010). *Davidson's Principles and Practice of Medicine*. illust. Robert Britton (21st Ed.). Edinburgh: Churchill Livingstone/Elsevier. p. 838.
- **Eda A**, Osawa H, Satoh K, et al (2003). Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. *J gastroenterol*. 38:14-22.
- **Epstein M A**, Achong B, Barr Y (1964). Virus particles in cultured lymphoblasts from Burkitt's lymphoma. *Lancet*, 1: 702-703.
- **Epstein, M. A**, Barr, Y. M, Achong, B. G (1964). Virus particles in cultured lymphoblasts from Burkitt's Lymphoma, *lancet*; 15:702 – 703.
- **Guan S**, Liu B, Zhang C, Lee KH, Sun S, Wei J(2013). Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma. *Clin Transl Oncol*; 15:825-9.
- **Guo M**, House MG, Suzki H, Yey, Brock MV, Lu F, Liu Z, Rustgi AK, Herman JG (2007). Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. *Intj cancer*, 15; 121(6):1219-26.
- **Hamad, H. M. A** (2011). Cancer initiatives in Sudan *Annals Oncology*; 17: viii 36.
- **Henle G.**, Henle W (1979). Seroepidemiology of the virus Epstein M. A. Achong B. G. Ed. *The Epstein - Barr virus*, Springer-Verlag Berlin 1979. pp. 297-320,

- **Hirano I**, Gilliam J, Goyal RK (2000). Clinical and manometric features of the lower esophageal muscular ring. *Am J Gastroenterol.* ; 95(1):43-9.
- **JinY**, Guan S, Liu L, Sun S, Lec KH, Wei J (2014). Anti – p16 autoantibodies may be a useful biomarker for early diagnosis of esophageal cancer. *Asia pacjclin oncol.*
- **Jiny**, Guans, Liu L, Sun S, Lee K H, Wei J (2014). Anti – pr6 – antibodies may be useful biomarker for early diagnosis of esophageal cancer .*Asia pacj clin oncol.*
- **John H. Dirckx** (1997). *Stedman's Concise Medical and Allied Health Dictionary* (3rd Ed.). Williams and Wilkins. p. 463.
- **Joseph S Pagano** (1999). Epstein Barr virus: the first human tumor virus and its role cancer. *Proceedings of the association of American physicians*; iii (6) 573 – 580.
- **Kieff E**, Rickinson A. B (2001). Epstein-Barr virus and its replication Ed. 4 Fields B. N. Knipe D. M. Howley P. M. eds. *Fields Virology, Vol. 2: pp. 2511-2575*, Lippincott-Raven Philadelphia, PA.
- **Knox P G**, Li Q X, A B and Young L S (1996). *Virology*; 215: 40 – 50.
- **Lambert.R**, Hainaut. P (2007). Epidemiology of esophagogastric cancer. *Best practice & Research Clinical Gastroenterology*; 21:921 – 945.
- **Lawrence S**, Young, Paul G, Murray (2003). Epstein Barr virus and oncogenesis from latent agenes to tumors. *Oncogene*; 22; 5108-5121.
- **Levine**, Richard M. Gore, Marc S (2010). *High-yield imaging*. (1st Ed.). Philadelphia, Pa.: Saunders/Elsevier. p. 151.
- **Li J Y**. (1982). Epidemiology of esophageal cancer in China. *NCI Monogr.* 62: 113 – 120.
- **Liang-Shun**, Wang, Kuan-Chih Chow. Yu-Chung, Wu, Wing-Yinli, Min-Hsiung Huang (1999). Detection of Epstein Barr virus in esophageal squamous cell carcinoma in Taiwan. *The American Journal of gastroenterology*; 44(10); 2834-2839.
- **Liebowitz D**, Kieff E, Roizman B, Whitley R. J, Lopez C (1993). *The Human Herpesvirus*, pp. 107-172, Raven Press New York.

- **Linde A**(1996). Diagnosis of Epstein-Barr virus-related diseases. *Scand. J. Infect. Dis.*, 28 (Suppl. 100): 83-88.
- **Longecker, R, Kieff, E** (1990). A second Epstein Barr virus membrane protein (LMP-1) is expressed in latent infection and co-localizes with LMP-1. *The Journal of Virology*; 64:2319 - 26.
- **Malik MO, Zaki EL Diaz, Elmasrish** (1976). Cancer of the alimentary tract in Sudan; a study of 546 cases. *Cancer*, 37(5) 2533-42.
- **Masashi Fukayama** (2010). Epstein Barr virus and gastric carcinoma. *Pathology international*; 60:337-350.
- **Moore, Keith L, Agur, Anne M.R** (2002). *Essential Clinical Anatomy* (2nd Ed.). Lippincott Williams & Wilkins. p. 145.
- **Müller M, Gockel I, Hedwig P, Eckardt AJ, Kuhr K, König J, et al** (2011). Is the Schatzki ring a unique esophageal entity? *World J Gastroenterol*. Jun; 17(23):2838-43.
- **Murray R. J., Kurilla M. G, Brooks J. M, Thomas W. A, Rowe M, Kieff E, et al** (1992). Identification of target antigens for the human cytotoxic T-cell response to EBV: implications for the immune control of EBV-positive malignancies. *J. Exp. Med.*, 176: 157-168.
- **Niedobitek G, Hansmann ML, Herbst H, Young LS, Dienemann D, Hartmann CA, et al** (1991). Epstein Barr virus and carcinomas: undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus. *J pathol*: 165:17 -24.
- **Niedobitek G, Young L. S, Herbst H** (1997). Epstein-Barr virus infection and the pathogenesis of malignant lymphomas. *Cancer Surv.*, 30: 143-161
- **Parkin, D** (2006). The global health burden of infection associated cancer in the year 2002. *International Journal of cancer* (1993) ; 118: 3044.
- **Parkin, D, Ferlay J, Hamdi- Cherif M, sitas F** (2003). *Cancer in Africa: Epidemiolo prev*, IARC scientific publication. IARC: Lyon; 153.
- **Parkin, D.M, Bray F, ferlay J** (2005). Global cancer statistics, 2002. *CA cancer Jclin* ; 55(2) :74 – 108.
- **Reda S S, Zeina G, Mahmoud A and Meixu** (2011). CDX2 as marker for intestinal differentiation: its utility and limitations

National Center For Biotechnology information
www.ncbi.nlm.nih.gov/53:1396.

- **Reedman, B** and Klein, G (1973). Cellular Localization of an Epstein Barr virus (EBV) associated complement fixing antigen in producer and non producer lymphoblastoid cell. *International Journal of cancer*; 11:499 – 520.
- **Rickinson A**, Young L, Rowe M(1987). Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. *J. Virol.*, 61: 1310-1317.
- **Rickinson A. B**, Kieff E, Knipe D. M., Howley P. M (2001.) *Fields Virology*, Vol. 2: pp. 2575-2629, Lippincott-Raven Philadelphia, PA.
- **Roizman B** (1990). Herpesviridae: a brief introduction Fields B. N. Knipe D. M. eds. *Virology* (1990), Ed. 2, Version 2. 1787-1794, Raven Press New York.
- **Sample J**, Young L, Martin B, Chatman T, Kieff ., Rickinson A, et al(1990). Epstein-Barr virus types 1 and 2 differ in the EBNA-3A, EBNA-3B, and EBNA-3C genes. *J. Virol.*, 64: 4084-4092.
- **Sbih-Lammali F**, Djennaoui D, Belaoui D, Bouguermouh A, Decaussin G, Ooka T(1996). Transcriptional expression of Epstein-Barr virus genes and proto-oncogenes in north African nasopharyngeal carcinomas. *J. Med. Virol.*, 49: 7-14.
- **Shaw-Smith, C** (2005). "Esophageal atresia, tracheo-esophageal fistula, and the VACTERL association: review of genetics and epidemiology". *Journal of Medical Genetics* **43** (7): 545–54.
- **Shibata D**, Weiss LM (1992). Epstein Barr virus. Associated gastric adenocarcinoma, *American Journal of pathology*; 140:769 - 74.
- **Shu C. H**, Chang Y. S, Liang C. L, Liu S. T, Lin C. Z, Chang P (1992). Distribution of type A and type B EBV in normal individuals and patients with head and neck carcinomas in Taiwan. *J. Virol. Methods*, 38: 123-130.
- **Shunji Mizobuchi**, Hiromi Sakamoto, Yuji Tachimon, Hoichi Kato, Hiroshi Watanabe, Masaaki Terada (1997). Absence of Human Papilloma virus – 16 and -18 DNA and Epstein Barr virus DNA in esophageal squamous cell carcinoma. *Japanese Joournal of Clinical Oncology*; 27 (1) 1 -5.

- **Sinclair, A**, Palermo, I, Peters, G (1994). EBNA-2 and EBNA LP co operate to cause G0 to G1 transition during immortalization of resting human B lymphocyte by Epstein Barr virus. *European Molecular Biology Organization Journal*; 13:3321 – 3328.
- **Sixby J. W**, Shirley P, Chesney P. J, Buntin D. M, Resnick L (1989). Detection of a second widespread strain of Epstein-Barr virus. *Lancet*, 2: 761-765.
- **Smithard DG**, Smeeton NC, Wolfe CD (2007). "Long-term outcome after stroke: does dysphagia matter?" *Age Ageing* 36 (1): 90–4.
- **Streher, L**, Campos .V, Mazzini. G, Binato M, Meurer. L, Edelweiss M, et al (2014) CDX2 Overexpression in Barrett's Esophagus and Esophageal Adenocarcinoma. *Journal of Cancer Therapy*, 5, 657-663.
- **Sugiura M**, Imai S, Tokunaga M, Loizumi S, Uchizawo M, Okamoto K and Osato T (1996). *Br.J – cancer*; 74:625 – 631.
- **Swaminathan S**, Tomkinson B, Kieff E, (1991). Recombinant Epstein Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates invitro. *Proc. Natl. Acad. Sci. USA*, 88:1546-1550.
- **Syrijanen KJ**, (2002). HPV infection and esophageal cancer. *J Clin Pathol* 55(10):721-728.
- **Tan L. C**, Annels N, Rickenson A. B, Hansasuta P, O'Callaghan C. A, Rowland-Jones S, et al (1999). A reevaluation of the frequency of cytotoxic T-cells specific for Epstein-Barr virus in long-term virus carriers. *J. Immunol.*, 162: 1827-1835.
- **Thompson MP** (2004). Epstein Barr virus and cancer. *Clinical Cancer Research. Clin cancer res.aacr*:17:2196
- **Toczyski, D**. Matera, G, Ward, D (1994). The small RNA EBER binds and relocalises ribosomal protein L22 in EBV infection human B- lymphocytes. *The proceeding of the National Academy of Science of the United States American*; 91: 3463 – 7.
- **Tokunaga M**, Uemura Y, Tokudome T, Ishidate T, Masuda H, Okazaki E, et al (1993). Epstein Barr virus related gastric cancer in Japan: A molecular patho – epidemiological study. *Acta pathol jpn*; 43: 574 – 81.

- **Tong lin**, Xinyan Zhang, Chikwong SO, Su Wang, Peng Wang, liying Yan, et al (2006). Regulation of CDX2 expression by promoter methylation, and effects of CDX2 transfection on morphology and gene expression of human esophageal epithelial cells.
- **Tutuian R**, Castell D (2006). "Esophageal motility disorders (distal esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter): modern management". *Curr Treat Options Gastroenterol* **9** (4): 283–94.
- **U.S. National Library of Medicine** (2015). 8600 Rockville Pike, Bethesda, MD 20894 U.S. Department of Health and Human Services National Institutes of Health Page last updated: 12 January 2015.
- **Wang**, D, Liebowitz, D, Kieff, E (1995). An EBV membrane protein expressed in immortalized lymphocytes transform established rodent cells. *Cell*; 34: 831- 40.
- **Wilson**, J, Weinberg,W, Johnson, R (1990). Expression of the BNLF-1 oncogen of Epstein Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. *Cell*; 61:13-27.
- **Winters GR 3rd**, Maydonovitch CL, Wong RK (2003). Schatzki's rings do not protect against acid reflux and may decrease esophageal acid clearance. *Dig Dis Sci.*; 48(2):299-302.
- **Wolf H**, Zur Hausen H, Becker V (1973). EB viral genomes in epithelial nasopharyngeal carcinoma cells. *Nature*; 44:245- 247.
- **Yanai H**, Hirano A, Matsusaki K, Kawano T, Miura O, Yoshida T, et al (2003). Epstein Barr virus association is rare in esophageal squamous cell carcinoma. *Intj gastrointest cancer*; 33:165-170.
- **Ye L**, Guan S, Zhang C, Lee KH, Sun S, Wei J, et al(2013). Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma. *Tumour Biol*; 34:1873-7.
- **Young L. S**, Rooney C. M, Sculley T. B, Moss D. J, Rupani H., Laux G, et al(1987). New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. *J. Gen. Virol.*, 68: 2853-2862.
- **Young, L. S**, Rickinson, A (2004). Epstein – Barr virus: 40 years on. *Nature Reviews cancer*; 4 (10): 757- 768.

- **Zuckerman J**, Banatvala E, Pattisonj R and Griffiths PD (2004). Principle and practice of clinical virology:5th end. Schoub. PP. 125-126.
- **Zurh. H** (1991). Viruses in human cancer. Science; 254:1167 – 1173.